Verona Pharma (VRNA) reported a Q4 loss Thursday of $0.05 per diluted share, compared with a loss of $0.02 a year earlier.
Analysts polled by FactSet expected a loss of $0.19.
Revenue for the quarter ended Dec. 31 was $36.7 million. The company did not report any revenue in the year-ago quarter.
Analysts surveyed by FactSet expected $33 million.
As of Dec. 31, the biopharmaceutical firm reported $399.8 million in cash and cash equivalents.
Shares of the company rose nearly 4% in recent premarket activity.
Price: 66.00, Change: +2.48, Percent Change: +3.90
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。